Astria Therapeutics (ATXS) EPS (Basic): 2017-2018
Historic EPS (Basic) for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$0.85.
- Astria Therapeutics' EPS (Basic) rose 64.14% to -$0.85 in Q4 2018 from the same period last year, while for Dec 2018 it was -$5.79, marking a year-over-year increase of 6.76%. This contributed to the annual value of -$5.12 for FY2018, which is 59.43% up from last year.
- Astria Therapeutics' EPS (Basic) amounted to -$0.85 in Q4 2018, which was down 962.50% from -$0.08 recorded in Q3 2018.
- In the past 5 years, Astria Therapeutics' EPS (Basic) ranged from a high of -$0.08 in Q3 2018 and a low of -$3.11 during Q3 2017.
- In the last 2 years, Astria Therapeutics' EPS (Basic) had a median value of -$1.42 in 2018 and averaged -$1.50.
- The largest annual percentage gain for Astria Therapeutics' EPS (Basic) in the last 5 years was 97.43% (2018), contrasted with its biggest fall of 602.44% (2018).
- Astria Therapeutics' EPS (Basic) (Quarterly) stood at -$2.37 in 2017, then soared by 64.14% to -$0.85 in 2018.
- Its EPS (Basic) stands at -$0.85 for Q4 2018, versus -$0.08 for Q3 2018 and -$1.98 for Q2 2018.